The earnings results for CRISPR Therapeutics (NASDAQ: CRSP) for Q4 were made public on Thursday, February 12, 2026 at 04:00 PM. Here's a comprehensive overview of the announcement. CRISPR Therapeutics ...

CRISPR Therapeutics overview after recent trading moves CRISPR Therapeutics (CRSP) has seen mixed trading recently, with the stock up about 2% over the past day but showing declines over the past week ...

CRISPR Therapeutics stays a Hold as CASGEVY launch lags; watch cash burn, revenue delays, and CTX310/CTX611 catalysts for 2026. Click here to read now.

What is CRISPR gene editing? CRISPR gene editing technologies enable changes to be made to DNA at specific regions. These changes can involve DNA insertion or deletion, or base pair disruption and can ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its ...

CRISPR Therapeutics is a gene therapy and gene editing company focused on developing gene-based medicines using CRISPR and Cas9 technologies. The company recently gained approval for Casgevy, a cure ...

Labroots invites you to the 8th Annual CRISPR Virtual Event Series 2025, taking place on October 22nd, 2025! This event will explore the expanding frontier of CRISPR technology, with sessions covering ...

In this interview conducted at SLAS EU 2023 in Brussels, Belgium, we spoke to Ulrike Künzel, Associate Director in the Functional Genomics department at AstraZeneca, about the application of arrayed ...